Skip to main content
. 2011 May 23;96(10):1512–1520. doi: 10.3324/haematol.2010.036814

Figure 5.

Figure 5.

A monoclonal antibody (mAb) directed against CD229 exerts strong complement-(CDC) and antibody-dependent cytotoxic (ADCC) effects on myeloma cells. When added at different concentrations to cultures of myeloma cell lines MOLP-8 (CDC) or U-266 (ADCC), a monoclonal antibody directed against CD229 exerted significant cell- (left) and complement-dependent (right) cytotoxicity, respectively. Dots indicate mean percentage (±SEM) of maximal cytotoxicity in an lactate dehydrogenase release assay 4 h after addition of CD229 mAb.